title: Dasatinib-related chylothorax.
abstract: Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature.
authors: Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-Oncology, Keelung, Taiwan. E-mail: liting@adm.cgmh.org.tw.
authors: Yen Min
authors: YM
authors: Huang
authors: Cheng Hsu
authors: CH
authors: Wang
authors: Jen Seng
authors: JS
authors: Huang
authors: Kun Yun
authors: KY
authors: Yeh
authors: Chien Hong
authors: CH
authors: Lai
authors: Tsung Han
authors: TH
authors: Wu
authors: Pei Hung
authors: PH
authors: Chang
authors: Pei Hung
authors: PH
authors: Chang
authors: Yueh Shih
authors: YS
authors: Chang
authors: Yii Jenq
authors: YJ
authors: Lan